Understanding the metabolic fate of peptide therapeutics across species is essential for informed drug development. This case study presents a systematic in vitro investigation into the hepatic metabolism of the bioactive peptide GLP‑1(28–36)amide, using a high‑resolution mass spectrometry‑based workflow across multiple preclinical species and humans.

Key Highlights

• Comprehensive metabolic profiling across mouse, rat, dog, monkey, and human hepatocytes
• Highly conserved pathways with clear species and gender related differences in metabolite abundance
• A robust, decision enabling DMPK strategy for peptide therapeutics
• Practical framework capturing both Phase I and Phase II metabolism for oligopeptide modalities

Download the full case study for a detailed overview of the metabolic pathways, species comparisons, and analytical methodology.